[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641909":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":86,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral cannabis (placebo)","PLACEBO_COMPARATOR","Participants will receive placebo oral cannnabis",[13,14],"Drug: Inhaled Cannabis","Drug: Intranasal Opioid",{"label":16,"type":17,"description":18,"interventionNames":19},"Oral cannabis (active)","EXPERIMENTAL","Participants will receive active oral cannabis",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Inhaled Cannabis","Participants will receive inhaled cannabis and placebo",[16,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Intranasal Opioid","Participants will receive intranasal opioids and placebo",[16,9],[32],{"name":33,"affiliation":34,"role":35},"Shanna Babalonis, PhD","University of Kentucky College of Medicine","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Paul Nuzzo","CONTACT","859-323-0002","paul.nuzzo@uky.edu",[43],{"facility":5,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Lexington","Kentucky","40508","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-84.47772,37.98869,{"lat":53,"lon":52},[56,57],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":35,"investigatorFullName":33,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Associate Professor","100641909","phase-1-cannabis-and-opioid-use-disorder-study-2-100641909",false,"NCT07661446","Cannabis and Opioid Use Disorder, Study 2","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder\n\nExclusion Criteria:\n\n* Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids","ALL","18 Years","55 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.",[77,78],"Opioid Use Disorders","Cannabis Use",[80,81,82,83,84,85],"Cannabis","marijuana","opioid","opioid use disorder","opioid withdrawal","opioid interaction","NOT_YET_RECRUITING","2026-06-22",{"date":89,"type":90},"2026-06-26","ACTUAL",{"date":92,"type":71},"2026-07-30",{"date":94,"type":71},"2030-01-30",{"name":5,"class":6},1]